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Abstract
Background and Aim: During prostate development, mesenchymal-epithelial interactions regulate organ growth and
differentiation. In adult prostate, stromal-epithelial interactions are important for tissue homeostasis and also play
a significant role in prostate cancer. In this study we have identified molecules that show a mesenchymal expression pattern
in the developing prostate, and one of these showed reduced expression in prostate cancer stroma.
Methodology and Principal Findings: Five candidate molecules identified by transcript profiling of developmental prostate
mesenchyme were selected using a wholemount in situ hybridisation screen and studied Decorin (Dcn), Semaphorin6D
(Sema6D), SPARC/Osteonectin (SPARC), Sprouty1 (Spry-1) and Tsukushi (Tsku). Expression in rat tissues was evaluated using
wholemount in situ hybridisation (postnatal day (P) 0.5) and immunohistochemistry (embryonic day (E) E17.5, E19.5; P0.5;
P6; 28 & adult). Four candidates (Decorin, SPARC, Spry-1, Tsukushi) were immunolocalised in human foetal prostate (weeks
14, 16, 19) and expression of Decorin was evaluated on a human prostate cancer tissue microarray. In embryonic and
perinatal rats Decorin, Semaphorin6D, SPARC, Spry-1 and Tsukushi were expressed with varying distribution patterns
throughout the mesenchyme at E17.5, E19.5, P0.5 and P6.5. In P28 and adult prostates there was either a decrease in the
expression (Semaphorin6D) or a switch to epithelial expression of SPARC, and Spry-1, whereas Decorin and Tsukushi were
specific to mesenchyme/stroma at all ages. Expression of Decorin, SPARC, Spry-1 and Tsukushi in human foetal prostates
paralleled that in rat. Decorin showed mesenchymal and stromal-specific expression at all ages and was further examined in
prostate cancer, where stromal expression was significantly reduced compared with non-malignant prostate.
Conclusion and Significance: We describe the spatio-temporal expression of Decorin, Semaphorin6D, SPARC, Spry-1 and
Tsukushi in developing prostate and observed similar mesenchymal expression patterns in rat and human. Additionally,
Decorin showed reduced expression in prostate cancer stroma compared to non-malignant prostate stroma.
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Introduction
Mesenchymal-epithelial interactions, mediated via cell-cell
signalling, play a crucial role in specification of mammalian
organs such as the prostate, kidney, lung, and mammary gland
and also in tissue homeostasis of adult tissues. Mesenchyme is the
embryonic precursor of adult stroma. In males the prostate
differentiates and grows from the urogenital sinus and is regulated
by testicular androgens. In females, the urogenital sinus develops
into the uterus and vagina, though it will form a prostate if
exogenous androgens are administered. Androgen effects are
mediated via the androgen receptor (AR) and studies in rodent
models have demonstrated that AR is expressed initially in the
mesenchyme and subsequently in the epithelium of the developing
prostate. Tissue recombination experiments using mesenchyme
and epithelium from either wild type or AR-deficient mice
revealed that a prostate can only develop when the mesenchyme
has a functional AR, while epithelial AR is not required [1–3].
The concept of embryonic mesenchymal and adult stromal cells as
mediators of organ-specificity was underlined by a study that
demonstrated diversity and positional memory in adult human
fibroblasts [4]. In the normal human adult prostate the majority of
the stromal compartment is made up of smooth muscle cells and
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fibroblasts, while the remainder consists of endothelial cells,
pericytes, lymphocytes and macrophages [5].
Recent studies have highlighted a role for the stromal
compartment in regulation of cancer cell progression, which is
now generally accepted [6]. Within the tumour microenvironment
cancer-associated fibroblasts (CAF) have been proposed as a key
source of pro-tumourigenic paracrine mediators [7–9]. TGFb1 is
one of the factors secreted by cancer-associated fibroblasts (CAF)
and can act in an autocrine or paracrine loop by binding to the
receptor complex TGFbRI/II on stromal and/or epithelial cells in
breast and prostate cancer cells [10]. The pro-tumourigenic
potential of TGFb1 was shown when the genetic ablation of the
TGFbRII in fibroblasts resulted in reduced tumour growth in
a mouse model [10,11]. Another important aspect of stromal pro-
tumourigenic activity is the heterogeneity of fibroblast subpopula-
tions and the lack of appropriate markers for them. Several CAF
markers have been proposed but identification of distinct
subpopulations co-expressing some of them and the contribution
of these subpopulations to tumour growth is recently emerging
[12–14].
There is a clear relationship between developmental signalling
and disease. In the Dunning rat model of prostate cancer, the
inclusion of embryonic mesenchyme reduced tumour growth,
underlining the instructive power of mesenchymal cells on
malignant cells [15]. Additionally, the McNeal hypothesis
suggests that developmental pathways are re-activated in
prostatic disease [16].
Thus, the identification of mesenchymal/stromal mediators of
mesenchymal-epithelial communication is paramount for the
understanding of development and disease of an organ. Secreted
or membrane-bound proteins appear to be the most likely
mediators of stromal/epithelial paracrine signalling.
In a previous study from our group, serial analysis of gene
expression (SAGE) of mesenchyme from the neonatal rat
urogenital tract identified 219 putative ‘mesenchymal’ transcripts
that were expressed at higher levels in mesenchyme than adjacent
epithelial tissue. This list might contain candidates for paracrine
mediators of mesenchymal-epithelial dialogue [17]. Within the
219 candidate transcripts we identified a subset that encoded
secreted or membrane-bound molecules, which are the most likely
candidates for mesenchymal-epithelial interaction. To date, we
have analysed and validated the expression of some of these
candidates in prostate development. We demonstrated that Dlk1
and Notch2 signalling was important for branching as well as
epithelial and smooth muscle differentiation in prostate organ
culture systems [18]. The receptor EphB3 and its ligand EphrinB1
were also detected in prostate mesenchyme, and organ culture
with EphrinB1-Fc ligand resulted in increased organ area but
decreased budding with enlarged bud tips, while incubation with
EphB3-Fc receptor reduced organ size and reduced budding [19].
Pleiotrophin (Ptn) was found to be expressed in developing
prostate mesenchyme and it regulated the growth of developing
mesenchyme, epithelium and CAFs. Additionally, androgen
signalling increased Ptn expression [20].
Taken together, these studies suggest that a high proportion
of the candidates identified by our SAGE profiling play a role
in prostate development and disease. In the current study, we
have further analysed candidate molecules from our earlier
SAGE studies to identify those expressed in rat and human
prostate development, and in prostate cancer. Our rationale was
that identification of mesenchymally expressed molecules would
give a better understanding of stromal biology. We selected
secreted and membrane bound molecules identified in our
SAGE studies and performed a wholemount in situ hybridisa-
tion screen (WISH) to define whether they showed mesenchy-
mal expression.
Here we show five candidates identified by WISH screen that
were confirmed as showing mesenchymal expression: Decorin,
Semaphorin6D, SPARC, Spry-1 and Tsukushi (Table 1). These were
examined during rat and human prostate development via
immunohistochemistry.
Decorin and Tsukushi were the only candidates with stromal-
only expression and were subsequently investigated in prostate
cancer (PCa) tissues. Decorin showed a significant downregulation
in comparison to non-malignant tissues, while Tsukushi expression
did not show any differential expression.
Results
Identification and Confirmation of Mesenchymally
Expressed Transcripts
In a previous study from our laboratory, SAGE analysis of
rat prostate mesenchyme identified 219 transcripts that were
expressed in inductive mesenchyme; these were promising
potential regulators of organogenesis. Our SAGE profiling
studies used the female prostate anlagen, termed VMP, since
it lacked epithelia and our goal was to identify non-epithelial
transcripts. Fig. 1A shows the homology between the mesen-
chyme of female and male urogenital tract (UGT) at P0.5, and
the important subregions of mesenchyme are shaded in green.
These SAGE studies identified transcripts likely to be expressed
within the mesenchyme [17]. Here, we focused on secreted or
membrane-bound molecules within the 219 transcript list as the
most logical candidates for mesenchymal-to-epithelial signalling.
To define which of our candidate molecules showed mesenchy-
mal/stromal specific expression patterns, a small WISH screen
was performed. Five candidates Decorin, Semaphorin6D, SPARC,
Spry-1 and Tsukushi were confirmed as mesenchyme-expressed in
this screen and chosen for further investigation (Figure 1B,
Table 1). Fig. 1B illustrates the numbers of transcripts (identified
via ‘‘tags’’ from the 39 end of the mRNA), normalised per
million tags to account for different tag counts between
libraries), which gave an approximation of transcript expression
level. From our list of five candidates, Decorin and SPARC were
the most highly expressed transcripts, and then Sema6D, Spry-1
and Tsku. Transcript levels were measured in two different
libraries (VMP and VSU) and the ratio between these gave an
indication of the likelihood of localisation to the VMP
mesenchyme, as the VMP is a subset of the VSU [17].
Molecules expressed ubiquitously gave ratios closer to 1, while
those showing VMP enrichment had ratios of 1.4 or greater.
Next, we performed WISH on rat neonatal urogenital tracts
(UGT) to determine the expression of mRNAs encoding our five
candidate molecules (Fig. 1C). Decorin and SPARC transcripts
showed a highly restricted expression pattern in mesenchyme of
the prostate (all lobes), while Sema6D, Sprouty1 and Tsukushi were
expressed in prostate mesenchyme as well as urethral mesen-
chyme. In general, distinct expression was visible in mesenchyme
adjacent to epithelial ducts and/or the wider epithelium-
surrounding mesenchyme in the ventral prostate (VP), the dorsal
prostate (DP), and the dorsolateral prostate (DLP). Decorin showed
the most restricted expression pattern in prostate mesenchyme
(Fig. 1C) and was clearly visible in mesenchyme adjacent to
epithelial buds, and was absent from non-prostatic mesenchyme
such as the urethral mesenchyme.
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Immunolocalisation of Decorin in Developing Rat
Prostatic Mesenchyme
We next examined the distribution of Decorin protein to
ascertain whether it showed a similar distribution to the mRNA,
and if it was also restricted to the mesenchyme. At E17.5 Decorin
was expressed in a subset of the UGT mesenchyme (Fig. 2A); the
bladder and adjacent to the prospective VP (Fig. 2B), the
expression was restricted to single cells with weak expression in
the cytoplasm and a strong signal at the cell surface. At E19.5
Decorin showed strong expression in the prostatic mesenchyme
and weaker staining around bladder with ‘‘hot spots’’ (Fig. 2D).
However, the prospective VP and DP also showed Decorin
expression but not as strong as that in the peri-urethral
mesenchyme (Fig. 2D, E). Neonatal P0.5 and P6.5 UGTs showed
similar staining with mesenchyme-only expression and a complete
absence in both urethral and prostatic epithelium (Fig. 2F–I).
Interestingly, this expression pattern differed from the WISH
pattern, where Decorin was found exclusively in mesenchyme
within prostatic lobes but not the peri-urethral area, and may
reflect secretion and diffusion of Decorin protein. At day 28,
Decorin expression was found in the stroma surrounding prostatic
ducts, and was absent from epithelia (Fig. 2J, K). At adulthood the
VP was morphologically fully differentiated, containing Decorin-
negative epithelia, and Decorin-positive stroma (Fig. 2L, M). In
summary, Decorin showed mesenchyme and stromal-specific
expression at all investigated developmental stages and a complete
absence in the epithelium. Furthermore, it was localised mainly to
the acellular interstitium.
Immunolocalisation of Tsku in Developing Rat Prostatic
Mesenchyme
Tsku expression at E17.5 and E19.5 was confined to
mesenchyme and smooth muscle, and showed a cytoplasmic
localisation in the VP and DP (Fig. 3A, B). At P0.5 and P6.5, Tsku
was absent in the epithelia but present in the smooth muscle and
mesenchyme that surrounds epithelial ducts in the VP and DP
(Fig. 3 C, D). The Tsku mRNA and protein showed similar
distribution patterns.
At day 28, the epithelium lacked Tsku and stromal expression
was less intense (Fig. 3 E). The fully differentiated adult VP showed
a further decrease in staining compared to P28. Additionally, Tsku
was observed in epithelial cells (Fig. 3 F).
Immunolocalisation of Semaphorin6D, SPARC and Spry-1
in Developing Rat Prostatic Mesenchyme
Semaphorin6D was expressed in the mesenchyme, including
the VP anlagen, at E17.5 to E19.5 (supplementary Fig. S1A, B),
perinatal VP and DP lobes, and at P6.5 UGTs but was absent in
the epithelia (Fig. S1 C, D). Surprisingly, immunostaining was
confined to the nuclei although Semaphorins are usually reported
to be localised at the plasma membrane. Nevertheless, WISH
pattern and protein detection were consistent in P0.5 UGTs.
However, in fully differentiated adult VP, only leukocytes were
found to express Semaphorin6D (Fig. S1F). In summary, the
Semaphorin6D expression was strongest and most consistent in
the mesenchyme of E17.5 to P0.5 UGTs with nuclear
localisation.
Immunostaining of SPARC was not detectable in E17.5 or
E19.5 old UGTs (data not shown). Weak mesenchymal
expression in the VP and DP was observed at P0.5 and was
absent from the epithelium (Fig. S2A). SPARC was expressed in
the mesenchyme surrounding epithelial buds at both P0.5 and
P6.5 but its staining was more prevalent and intense in the
latter stage. In contrast, there was no epithelial SPARC
expression detectable (Fig. S2B). The patterns for SPARC
detection via WISH and immunohistochemistry (IHC) were
consistent in P0.5 UGTs.
At P28 and adult, SPARC expression was very low in the
stroma at P28 (Fig. S2C) and absent in adult VP (Fig. S2D).
However, there was a strong expression in a subset of epithelial
luminal cells, localised to the nuclei. In summary, while absent in
embryonic and foetal stages, SPARC was expressed in the
mesenchyme during the branching period but there is a stromal-
epithelial reversal of expression during the formation and
maintenance of adult prostate with strong expression in some
epithelial cells but not the stroma.
Rat Spry-1 protein was detected in the mesenchyme in
developing VP in E17.5 and E19.5 UGTs (Fig. S3A, B). At
perinatal stage P0.5 (Fig. S3C), the Spry-1 detection was
strongest in the mesenchyme adjacent to epithelial ducts and
Table 1. Overview of candidate genes.
Official gene
symbol (rat) Official gene name Other names
Accession numbers/
Uni gene code Protein function
Dcn Decorin bone proteoglycan II; PG40; PG-S2;
dermatan sulfate proteoglycan-II
(DSPG)
NM_024129.1/Rn.106103 ECM protein; binds the N-terminal region of collagen
VI; involved in kidney and lung branching; potential
tumour suppressor [29,32,47,48]
Sema6D Semaphorin6D – NM_001107768.1/Rn.8257 Family of Semaphorin axon guidance molecules [35]
but Sema6D is involved in heart development [49]
SPARC secreted protein,
acidic, cysteine-rich
Osteonectin (ON); basement-
membrane protein 40
(BM-40)
NM_012656/Rn.98989 Secreted structural protein involved in branching of
lung [50]and mesonephros [51]; suppresses
inflammation in ovarian cancer tumour
microenvironment; tumour-suppressive in Tramp
mouse model of PCa [52]
Spry-1 Sprouty homologue 1 – NM_001106427.1/Rn.22787 FGF antagonist; crucial for uretic bud branching for
kidney formation and also involved in prostate cancer
[53–56]
Tsku Tsukushi hepatic protein EIIH; leucine-rich
repeat-containing protein 54; early
insulin-induced hepatic
gene protein
NM_001009965/Rn.8672 antagonizes FGF and BMP signalling in chicken and
Xenopus early neuronal embryonic development
[57–60]; Tsku gene knock out has small brain and
lacks commissure [61]
doi:10.1371/journal.pone.0042516.t001
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less intense in mesenchymal cells between ducts, and it was
localised adjacent to the nucleus rather than being distributed in
the cytoplasm (Fig. S3F). The patterns for Spry-1 detection via
WISH and IHC were comparable in P0.5 UGTs (Fig. S3C).
There was weak detection of Spry-1 within prostatic epithelial
ducts at P0.5 and was more pronounced at P6.5, while
mesenchymal Spry-1 expression remained unaltered (Fig. S3D).
In contrast, prostatic lobes at day 28 and adult VP showed
a reversal of Spry-1 expression compared with P0.5 UGTs. In
the differentiated state, the expression was minimal in stromal
cells but strong in the epithelium, in which Spry-1 is distributed
throughout the cytoplasm of basal and luminal cells (Fig. S3E,
F).
The Distribution of Decorin, SPARC, Spry-1 and Tsukushi
in Human Foetal Prostate
Next, we examined the protein localisation of Decorin, SPARC,
Spry-1 and Tsukushi in human foetal prostate. A wk 14 human
prostate shows early epithelial budding, similar to rat perinatal
stage P0.5 [21]; see also Fig. 4, two top rows). However, precise
correlation of developmental stages is difficult due to anatomical
differences, as rodents show paired and discrete lobes while the
human prostate is compact without lobular organization [21].
Decorin expression in human foetal prostates was confined to
the mesenchymal compartment and was completely absent in the
urothelium and prostatic epithelium at all developmental stages
(Fig. 4A–F). Notably, Decorin expression in the ventral smooth
Figure 1. Rat urogenital tract (UGT) anatomy and the expression of Decorin, Tsukushi, Semaphorin6D, SPARC, and Sprouty1 in
mesenchyme. A) Schematic overview of rat UGT anatomy at perinatal stage (P0.5) for the male (top) and female (bottom). The green shaded area
corresponds to inductive mesenchyme, which is found in both, male and female UGTs. The female VMP mesenchyme was used for SAGE gene
profiling studies, and our WISH screen aimed to identify those transcripts expressed in male prostate mesenchyme. Figure based on Thomson, 2001
[46]. B) Transcript expression levels of Decorin, Sema6D, SPARC, Spry-1 and Tsku obtained via SAGE profiling of P0.5 female rat VMP [17]. Transcripts
were identified via short, transcript-specific sequences called tags and their count reflects the transcript expression level. The ratio between VMP and
VSU tag counts represents the likelihood of restriction to the inductive mesenchyme; values at or over 1.4 suggested mesenchyme-specific
expression. C) Detection of Decorin, Sema6D, SPARC, Spry-1 and TskumRNA distribution via in situ hybridisation in male rat P0.5 UGTs. The small insets
show UGTs treated with the negative control sense RNA probes, scale bar is 1 mm Abbreviations: AP anterior prostate, DP dorsal prostate, DLP
dorsolateral prostate, VP ventral prostate, VMP ventral mesenchymal pad, VSU; VMP + smooth muscle + urothelium, SV seminal vesicle.
doi:10.1371/journal.pone.0042516.g001
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muscle areas was extremely low or absent (e.g. Fig. 4C, bottom of
panel).
We were unable to localise Semaphorin6D in human foetal
prostate due to poor antibody reactivity to human Sema6D (data
not shown).
SPARC expression showed stronger staining with increasing
foetal age and was predominantly expressed in the mesenchyme
(Fig. 4G–L). At wk14, expression was adjacent to endothelial cells
and was also present in smooth muscle at wk16 (Fig. 4K–L). At
both stages, the epithelium was devoid of SPARC expression. At
wk19, stromal staining was intense and found in most mesenchy-
mal cells (Fig. 4K–L), including endothelial capillary cells, and
with weak staining in the epithelia. The staining in the apical
region of epithelial suggests that the SPARC epithelial signal may
be non-specific (arrowhead in Fig. 4L) as prostate secretory
proteins can non-specifically bind some antibodies.
Spry-1 was found to be expressed in both, the epithelial and
mesenchymal compartments at all three ages (Fig. 4M–R). At
wk14, the epithelial localisation was at the basal membrane and on
top of the apical side of the luminal epithelial cells. Mesenchymal
expression was confined to small but intense spots that were
scattered throughout the mesenchyme (Fig. 4K–L). At wk16,
epithelial expression was absent from the basement membrane but
still present at the apical surface while mesenchymal expression
was localised to the cytoplasm of a subset of cells, including
endothelial cells. At wk19, epithelial expression was evenly
distributed throughout the basal and luminal cell layers, localised
to the cytoplasm and cell surface. Mesenchymal expression was
once again confined to small spots within a subset of fibroblastic
and endothelial cells.
Tsukushi was found in small mesenchymal subregions com-
pared with the other three proteins, and its prevalence was
minimal at all three stages (Fig. 4S–X). There was no clear
expression pattern in regard to cell type or area, instead it was
found in fibroblasts and endothelial cells, and was detected on the
apical side of some luminal epithelial cells at weeks 14, 16 and 19.
Decorin, SPARC, Spry-1 and Tsukushi showed striking
similarities in regard to mesenchymal localisation as well as
increase in staining intensity in both human and rodent, between
P0.5 to P6.5 and wk14 to wk19, respectively. The similarities in
protein distribution between rat and human suggest that these
molecules are mesenchymally expressed and may play important
roles in developmental growth and patterning of the prostate.
Expression of Decorin is Decreased in Prostate Cancer
Decorin and Tsukushi demonstrated the most mesenchyme-
specific expression patterns in developing rat and human prostate,
while Semaphorin6D, SPARC and Spry-1 showed both mesen-
chymal and epithelial expression. We decided to focus on
molecules showing mesenchyme-only expression and thus Decorin
and Tsukushi were taken forward for evaluation of expression in
prostate cancer and patient-matched controls.
Tissue micro arrays (TMAs) and samples of our own collection
of PCa were stained for Tsukushi but no difference was observed
Figure 2. Immunolocalisation of Decorin in the developing rat prostate. Developmental stages of E17.5 (A-C), E19.5 (D, E), P0.5 (F, G), P6.5
(H, I), P28 (J, K) and young adult (L, M) were investigated. At developmental stages E17.5, E19.5 the magnifications show the areas of prospective VP,
while at P0.5 and P6.5 the VP or DP are shown. Decorin was absent in epithelium and the smooth muscle compartment but present in the
mesenchyme/stroma. The expression was especially strong in mesenchyme adjacent to urethral and prostatic epithelium, as indicated by black
arrowheads and arrows. Notably, Decorin appeared to co-localise with structural fibres in the extracellular matrix, indicated by white arrowheads in I
and M. Legend: B bladder, BV blood vessel, C capillary, DP dorsal prostate, E epithelium, M mesenchyme, L lumen of prostatic ducts, S stroma, SM
smooth muscle, U urethra, VP ventral prostate. Scale bars: 200 mm in A, D, F, H and L, 400 mm in J, and 50 mm in all others. Please note that panel H
has been size adjusted – including the scale bar - and is not at the same magnification as panels A, D and F.
doi:10.1371/journal.pone.0042516.g002
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between PCa and non-malignant tissue (data not shown). Next, we
examined Decorin expression.
Representative areas of Decorin staining are shown in Fig. 5A,
B. Decorin staining was scored by a single blinded investigator
for the extent of stromal Decorin staining (0 = no staining,
1 =,1–20%, 2 =,20–50%, 3 =.50% of stromal area). Also,
the most prevalent intensity of staining in each tissue spot was
assessed (independent of the stained area size) with a non-linear
scoring system 0,1,2,3 with 0 being absence of staining, and 1,
2, and 3 representing increasing stain intensity. We assumed
that the staining intensity was in proportion to the actual
amount of Decorin protein. Between malignant and non-
malignant tissue, there was no difference in the extent of
stromal area of Decorin expression (Mann-Whitney test;
p = 0.45). However, we found a decreased intensity of Decorin
staining in malignant areas compared with non-malignant
control areas. In total we analysed 186 tissue spots from
commercial TMAs and tissue sections of TURP chips from 10
patients.
Statistical analysis with a non-parametric Mann-Whitney test
confirmed a significant decrease of intensity of stromal Decorin
staining in malignant areas compared with non-malignant control
areas (p = 0.0001, Fig. 5E). The results suggest a downregulation of
Decorin in PCa. We next examined a possible correlation between
Decorin staining intensity and Gleason score, however there was
no evidence of correlation (data not shown).
Discussion
Molecules expressed in prostate mesenchyme and stroma play
key roles in development, tissue homeostasis and diseases such
as cancer. We set out to identify molecules that showed
mesenchyme-specific expression in the prostate, and subsequent-
ly those that also showed dysregulated expression in prostate
cancer. Our starting point was a developmental gene expression
profiling study from our group which provided a list of 219
molecules that were potentially restricted to inductive prostate
mesenchyme. The transcript distribution of several of these
Figure 3. Immunolocalisation of Tsukushi in the developing rat prostate. Developmental stages of E17.5 (A), E19.5 (B), P0.5 (C), P6.5 (D), P28
(E) and young adult VP (F) were investigated. At developmental stages E17.5, E19.5 the magnifications show the areas of prospective VP, while at P0.5
and P6.5 it is either the VP or the DP. Tsku protein expression was mesenchymal/stromal only until P28 (arrows). However, in adult VP, there was
additional low expression in the epithelium (arrowhead in F). Interestingly, smooth muscle cells were also positive for Tsku (P0.5 to P28). Scale bars
equal 200 mm.
doi:10.1371/journal.pone.0042516.g003
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candidates was examined by wholemount in situ hybridization,
leading to the identification of five mesenchymally expressed
molecules during prostate development. One of these molecules,
the putative tumour suppressor Decorin, also showed down-
regulation in prostate cancer stroma.
Figure 4. Decorin, SPARC, SPRY-1 and TSKU protein expression in human foetal prostates at gestational weeks 14 to 19. Human
foetal prostates at gestational weeks 14, 16 and 19 are shown in the top two, middle two and bottom two rows, respectively (each age stage n= 1
tissue). The A–S, C–U and E–W rows represent overviews (scale bar = 200 um), while the B–T, D–V and F–X rows show magnifications (scale bar
= 50 mm). Each column shows the staining for one protein across the stated developmental time period, and insets show IgG negative controls. Only
Decorin expression was restricted to the mesenchyme, while SPARC and TSKU were also mesenchymal with a little epithelial expression at wk 19.
SPRY-1 showed expression in mesenchyme and some epithelial expression with increasing age. Arrows indicated examples of mesenchymal
expression while arrowheads indicate epithelial expression. Legend: d dorsal, e epithelium, ed efferent duct, s stroma, u urethra, v ventral.
doi:10.1371/journal.pone.0042516.g004
Stromal Factors in Prostate Development and Cancer
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Expression of Mesenchymal Molecules in Developing
Prostates
We have identified mesenchymal expression of Decorin, Sema-
phorin6D, SPARC, Sprouty1 and Tsukushi in perinatal P0.5 male rat
UGTs via WISH and their respective proteins via IHC. In all
cases, there was a very good correlation between WISH staining
and IHC detection of the molecules. The distribution of Decorin
protein showed peri-epithelial localisation that was not detected
via WISH. The Decorin antibody was validated in the Human
Protein Atlas Project (http://www.proteinatlas.org/) as specific for
human Decorin and as it is a secreted protein, we speculate that
the strong staining adjacent to the urothelium is the result of
secretion and diffusion.
Decorin, Semaphorin6D, SPARC, Sprouty1 and Tsukushi were
expressed in rat mesenchyme during E17.5 to P0.5. At P6.5 four
molecules showed mesenchymal-only expression with only Spry-1
showing expression in both mesenchyme and epithelium. When
prostate differentiation was nearly or fully complete at P28 and
adult, respectively, there were clear differences between groups:
the proteoglycans Decorin and Tsukushi had stromal localisation,
Semaphorin6D gained a weak expression in the epithelium but
was nearly completely absent in the stroma, whereas Spry-1 and
SPARC showed a reversal of patterns with strong expression
towards the epithelial compartment and near absence in the
stroma. From these data we conclude that amongst the currently
investigated molecules two retain stromal expression in the
differentiated prostate and the remainder either cease stromal
expression or switch to epithelial expression.
Mesenchymal Expression in Rat and Human Prostate
Development
There are recent reviews of comparative anatomy between
human and rodent [21] as well as comparisons of global gene
expression programmes in prostate development versus cancer
[22]. However, few studies so far compared mesenchymally
expressed genes and their protein products between the developing
rodent and human prostate [23]. In the current study we found
that the expression of Decorin, SPARC, Spry-1 and Tsukushi in
human prostate correlated well with the respective developmental
stages in the rat prostate, suggesting that the rat is a suitable model
for the study of human prostate development.
A Role for Decorin in Prostate Development and Cancer
Several functions have been described previously for Decorin in
development. Decorin is a small connective tissue proteoglycan
demonstrated to have multiple physiological functions including:
structural function, context-dependent inhibition or enhancement
of TGFb signalling, restricting mitosis, and other activities [24–
Figure 5. Decorin expression is decreased in prostate carcinomas. PCa tissue was stained via IHC for Decorin. A) A representative PCa tissue
spot showed less intense staining than B) a representative non-malignant tissue spot. Simultaneously processed prostate tissue from our own tissue
bank was used with non-specific IgG as negative control C) and anti-Decorin antibody as positive control (D), demonstrating specificity of staining.
The evaluation of DAB staining intensity for each tissue spot is shown in E), demonstrating a significantly lower scoring in PCa (n = 91) compared with
non-malignant controls (n = 20) (Mann Whitney test, two-tailed, p,0.0001). The boxes indicate the 25–75 percentiles while whiskers indicate the 10–
90 percentiles.
doi:10.1371/journal.pone.0042516.g005
Table 2. Primer sequences for the whole mount in situ
experiments.
Oligo name Sequence (59 to 39 orientation)
Product
size [bp]
Dcn F CGAAGACACATCTGAAGGTG 523
Dcn R CAGTCAACTGCATCTGGATG
Sema6D F TTCTGCCACAGTGGCTGATT 548
Sema6D R GCCTTGGTTTTGGTACTTTG
SPARC F CCCGAGACTTTGAGAAGAAC 518
SPARC R AGGCTGTGGATAGGCTATGG
Spry-1 F CAAGCCGTCATGACTTCTGG 535
Spry-1 R GTGAATCCAGAGCTGTGTGC
Tsku F CCAAGCTCAAGTGGGCAG 503
Tsku R GCATCGAAGTCCCTTTGC
doi:10.1371/journal.pone.0042516.t002
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27]. Various studies have shown that TGFb is important in
prostate organogenesis and can enhance the mitotic rate in
undifferentiated or less well differentiated epithelial cells at the tips
of budding prostate lobes in the rat [28]. We speculate that the
action of TGFb can be modulated by Decorin, as described during
lung branching where Decorin prevents the inhibitory activity of
TGFb in organ explants in vitro [29].
We identified Decorin as a stromally expressed molecule and
examined if it showed altered expression in prostate cancer (PCa)
stroma. In a PCa TMA we identified a reduction of Decorin
staining compared with non-malignant controls. This result differs
from a previous study that reported an increase in Decorin
expression in early stage prostate cancers [30]. It is possible that
the use of different antibodies and the relatively small number of
samples investigated in both studies could contribute to the
conflicting results. However, our finding of Decorin down-
regulation in PCa is supported by its activity as a tumour
suppressor in prostate cancer [31,32] and further investigation of
Decorin in prostate cancer is likely to be of value.
What is the Potential Role of Decorin in Prostate Cancer?
Decorin exerts pleiotropic effects in tumour suppression,
affecting multiple mechanisms and pathways.
In a model of colorectal cancer, Decorin was reported to
interact with and stabilise E-cadherin, thereby attenuating the
progression of colorectal cancer [33]. In another model system,
Decorin led to an acidification of the microenvironment and
cancer cells, resulting in the inhibition of migrating melanoma cells
in a co-culture system with fibroblasts [34]. Regarding specific
pathways, insulin-like growth factors (IGFs) are commonly
upregulated in cancers and activate IGF1R, which subsequently
activates the pro-tumourigenic PI3K-Akt pathway. Iozzo et al.
found Decorin to antagonise the action of IGF1R in bladder
cancer cells, which was in agreement with the findings that
Decorin was decreased at the mRNA and protein level in bladder
cancer tissue of patient samples [35].
Several of these diverse mechanisms could be relevant to
prostate cancer. Since the genes for glucose metabolism are highly
overexpressed in several cancers, including prostate, this indicates
the presence of the Warburg effect [36], which ultimately results in
acidosis. Hence, Decorin as main contributor to acidification of
the microenvironment appears unlikely in PCa, as it appears less
abundant in the prostate tumour stroma.
The idea of Decorin stabilising E-Cadherin appears unlikely for
the prostate, as Decorin is not expressed in prostate epithelial cells.
Also, previous reports showed that the most aggressive forms of
prostate cancer metastasis have the highest E-Cadherin expression
[37]. As such, the potential interaction between E-Cadherin and
Decorin in PCa is speculative.
Generally, the role of IGF1 and its cognate receptor IGF1-R are
well established to participate in tumourigenesis [38]. In regard to
PCa, there are bioinformatic studies demonstrating a correlation
between IGF1 levels and the onset of PCa. In one study, IGF1 was
identified as one of the top ten genes probable to drive prostate
cancer [39]. Another group found that IGF1 is likely to be secreted
from normal genomically stable cells towards the cancer cells,
thereby acting in a paracrine manner [40]. Inhibition of IGF1-R
via chemical compounds had inhibitory effects in vitro on PCa
colony formation in a 3D matrix [41]. Therefore we speculate that
studies into the interaction of Decorin and IGF1 signalling could
yield a better mechanistic understanding of PCa inhibition via
Decorin.
Furthermore, activated cancer-associated fibroblasts (CAF) are
part of the tumour microenvironment and well-known to support
tumour growth [7]. It was found that they secrete higher levels of
TGFb than morphologically normal prostatic fibroblasts [10].
TGFb acts as an autocrine signal to maintain CAF properties and
additionally signals to the neighbouring cells. It stimulates cancer
growth and angiogenesis in a paracrine manner as well as further
myo-differentiation of fibroblasts and thereby supports an overall
disease progression [42–45]. Hence, we speculate that Decorin
might interfere –among other things- with TGFb action and
exogenously administered Decorin protein could have potential
beneficial therapeutic effects.
Summary
In this study we describe detailed spatial-temporal expression of
Decorin, Semaphorin6D, SPARC, Sprouty1 & Tsukushi in
developing rat and human prostate. The expression patterns
showed evolutionary conservation emphasising the importance of
stromally restricted factors. We identified Decorin as a stromally
restricted molecule whose expression was down-regulated in
prostate cancer. These findings confirm the concept that de-
velopmental mesenchymal molecules are important to human
diseases such as prostate cancer. Further studies into Decorin’s
potentially tumour suppressive effects in prostate cancer are
warranted.
Materials and Methods
Ethical Statements
The use of human foetal reproductive tissues from medical
terminations of pregnancies was approved by the Lothian
Research Ethics Committee (study code LREC 08/S1101/1).
Table 3. Antibodies for Immunohistochemistry.
Antibody Raised in Manufacturer/provider Cat no. Lot no. final concentration (mg/ml)
Decorin rabbit Sigma-Aldrich HPA003315 A08795 0.150
Semaphorin6D rabbit AbCam Ab81255 831079 6.7
SPARC rabbit Santa Cruz sc-25574 F1505 2.0
Sprouty1 mouse Sigma-Aldrich WH0010252M1 08193-3H4 3.3
Tsukushi rabbit Sigma-Aldrich HPA008164 R02536 1.2
IgG fraction rabbit Dako X0903 00029041 0.15 to 6.7*
IgG 2ak mouse Sigma-Aldrich M5409 NA 3.3
*depending on concentration of primary antibody.
doi:10.1371/journal.pone.0042516.t003
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All participants gave informed written consent according to UK
national guidelines.
Patients undergoing transurethral resection of the prostate
(TURP) provided informed written consent. The use of their
TURP tissue was approved by the Eastern Multicentre Research
Ethics Committee, Cambridge, reference no. MREC 02/5/63.
The animal procedures included breeding & euthanising and
were carried out by trained staff to optimise animal health &
minimise suffering, respectively. Euthanisation was performed in
accordance with ‘schedule 1’, defined by the UK Animal Scientific
Procedures Act (1986).
Animals
The Wistar rat strain is an established model for investigating
prostate development. Wistar rats were housed under standard
conditions with 12 h/12 h light dark cycles and ad libidum access to
water and food. Animals were euthanised by cervical dislocation
and/or decapitation for organ dissection afterwards. Tissues were
micro-dissected from the urogenital tract (UGT) for which the
copulatory plug observation was taken as embryonic day 0.5
(E0.5), and the day of birth was designated P0.5.
Human Tissue
Gestational stage was determined by ultrasound scan and
confirmed by subsequent direct measurement of foot length. One
prostate each of 14, 16 and 19 weeks of gestation were dissected
into sterile PBS solution before fixation in Bouin’s solution on ice
for two hours.
Prostate cancer tissue was collected at the Western General
Hospital, Edinburgh, Scotland. 10 of the 34 collected samples
originated from patients naı¨ve to previous PCa-treatment and
their formalin-fixed prostate tissue samples were used for
immunohistochemistry. Their pathology details are given in
Tables S1, S2, S3.
Two commercial PCa TMAs were purchased from AccuMax
Array: TMA A222(II), lot 12210505231, contained malignant
samples in duplicates from 45 patients of which 6 were also used to
provide single-spot non-malignant control tissue. TMA A222(III),
lot 1221120707312, contained 45 PCa patient samples in
duplicates and provided 8 single control spots. The TMAs’
accompanying pathological data are described in Tables S2 and
S3. In addition, we used our own collection of PCa samples and
identified 10 patients that did not receive therapy prior to TURP
and hence had preserved tissue architecture (for pathological
details see Table S1). 74 TURP chips of the ten patients were
pathologically evaluated for malignant and non-malignant areas in
the first and last slide in a row of serial sections, from which slides
in between were used for Decorin staining. Up to two randomly
chosen fields of malignant and non-malignant areas each were
imaged and evaluated for Decorin staining.
Profiling Data
The tag profiling data were collected in a previous study [17]
and are accessible from the Gene Expression Omnibus (GEO)
data base under accession number GSE7899.
Whole Mount in Situ Hybridization (WISH)
Generation of DIG-labelled sense and antisense RNA probes
was undertaken using methods detailed previously [19]. The
sequences of the primers were checked via BLAST for target-
specificity and are given in Table 2. Tissue-specificity was checked
by normal RT-PCR and subsequent confirmation of expected
band size via agarose gel electrophoresis of PCR products.
P0.5 urogenital tracts (n = 50) were micro-dissected and fixed
overnight in 4% paraformaldehyde, dehydrated through graded
methanol, and stored in 100% methanol at 220uC; RNA in situ
hybridization was performed using the InsituPro VS robot (Intavis
Bioanalytical Instruments, AG, Cologne, Germany), using a pre-
viously published protocol [19]. In short, hybridization with DIG-
labelled probes was performed at 65uC for 16 h, followed by high
stringency washes. For detection, tissues were incubated with anti-
DIG antibody conjugated to alkaline phosphatase (1:2000; Roche)
at 18uC for 16 h. After washing, the colour was developed using
Nitro-Blue Tetrazolium Chloride/5-Bromo-4-Chloro-39-Indoly-
phosphate p-Toluidine Salt solution (Roche). Typical development
times were around 8 h. Digital images were acquired with a Leica
MZ6 stereo microscope (Leica Microsystems, Deerfield, IL) with
attached Leica ICA camera.
Immunohistochemistry
Immunolocalisation of candidates on rat and human tissues was
undertaken using specific antibodies and appropriate IgG negative
controls (Table 3). Rat tissues were obtained at E17.5 (n = 3 lit-
ters), E19.5 (n = 4 litters), P0.5 (n = 15 litters), P6.5 (n = 6), P28
(n = 4) and adults (3 months, n = 5). Tissues were fixed for two
hours on ice in Bouin’s, paraffin-embedded, sectioned at
5 microns and mounted onto frosted slides. Tissue slides were
dewaxed and rehydrated in a xylene/alcohol series, and antigens
retrieved via pressure cooking the sections in 0.01 M citrate buffer,
pH 6. The antigen detection and DAB staining was performed on
a Bond-Max robot (Leica Microsystems, Peterborough, UK) with
the Bond Polymer Refine Detection Kit (cat. No. DS9800; Vision
BioSystems bond, Newcastle upon Tyne, UK) according to the
manufacturer’s instructions. After the run, slides were dehydrated
in an alcohol/xylene series, mounted with Pertex (Histolab,
Gothenburg, Sweden) and cover slipped. Images were taken with
an Axiocam HRc digital camera (Zeiss, Welwyn Garden City,
UK) mounted on a Provis AX70 microscope (Olympus, Essex,
UK). Images were moderately white balanced without any loss of
information, assembled and annotated with Photoshop.
Statistical analysis. Data were analysed with GraphPadPr-
ism5 (GraphPad Software Inc., La Jolla, CA, USA) and statistical
tests were chosen as appropriate and indicated in the text.
Supporting Information
Figure S1 Immunolocalisation of Semaphorin6D in the
developing rat prostate. Developmental stages of E17.5 (A),
E19.5 (B), P0.5 (C), P6.5 (D) P28 (not shown, as it looks like adult)
and young adult VP (E) were investigated. At developmental stages
E17.5, E19.5 the magnifications show the areas of prospective VP
(also indicated by arrows in A, B), while at P0.5 and P6.5 it is
either the VP or the DP. Semaphorin6D was absent in any
epithelium and expressed only in mesenchyme from E17.5 until
P6.5 (arrows in A–D). However, at P28 and adult stages, it was
also found in epithelial cells and macrophages (arrowheads in E).
Note predominant localisation to the nuclei. Scale bar equals
200 um in A and all other panels are at the same scale.
(TIF)
Figure S2 Immunolocalisation of SPARC in the de-
veloping rat prostate. Developmental stages of E17.5 and
E19.5 did not show positive staining (data not shown). Stages P0.5
(A), P6.5 (B), P28 (C) and young adult VP (D) are shown. At
developmental stages P0.5 and P6.5 the magnifications show the
areas of either VP or DP. SPARC showed weak mesenchymal-
only expression at P0.5 and P6.5, localised to the cytoplasm
(arrows in A, B). However, at P28 and adult stages, there was
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strong staining in the nuclei of a subset of epithelial cells and
macrophages (arrowheads in C, D), while stromal expression was
very weak or absent. Scale bar equals 200 um in A, and all other
panels are at the same scale.
(TIF)
Figure S3 Immunolocalisation of Spry-1 in the develop-
ing rat prostate. Developmental stages of E17.5 (A), E19.5 (B),
P0.5 (C), P6.5 (D), P28 (E) and young adult VP (F) were
investigated. At developmental stages E17.5, E19.5 the magnifica-
tions show the areas of prospective VP, while at P0.5 and P6.5 it is
either the VP or the DP. Sprouty1 protein localisation was
mesenchymal only at E17.5 and E19.5 (arrows). At P0.5, the
expression was strong in the mesenchyme that surrounds epithelial
ducts, with very weak expression in the epithelium. At P6.5, the
epithelial expression was stronger than at P0.5 but still much
weaker than in the mesenchyme. At P28, the expression was
reversed: strong in the epithelium (arrowheads in E, F), weak in the
stroma; and also in adult VP. Scale bar equals 200 um in A, and
all other panels are at the same scale.
(TIF)
Table S1 Pathological details of pre-treatment-naı¨ve
PCa patients undergoing transurethral resection of the
prostate.
(XLS)
Table S2 Pathological details of PCa patients in the
tissue micro array A222(II).
(XLS)
Table S3 Pathological details of PCa patients in the
tissue micro array A222(III).
(XLS)
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